摘要
目的评价乌司他丁联合奥曲肽治疗重症急性胰腺炎的可行性,为重症急性胰腺炎患者治疗工作提供参考。方法选择我院2018年5月至2019年8月收治住院治疗的重症急性胰腺炎患者80例,随机分为对照组与试验组,对照组40例患者采取奥曲肽治疗,试验组40例患者采取乌司他丁联合奥曲肽治疗。对比两组重症急性胰腺炎患者的治疗效果、安全性、炎性因子水平。结果试验组重症急性胰腺炎患者治疗后临床疗效高于对照组,不良反应发生率低于对照组(P<0.05);两组血清IL-6、IL-8、TNF-α水平均低于治疗前,且试验组IL-6、IL-8、TNF-α低于对照组,P<0.05。结论对比单一治疗,乌司他丁联合奥曲肽治疗重症急性胰腺炎兼具安全性、有效性,且患者血清炎性因子水平改善明显。
Objective To evaluate the feasibility of ulinastatin combined with octreotide in the treatment of severe acute pancreatitis,and to provide references for the treatment of patients with severe acute pancreatitis.Methods We selected 80 patients with severe acute pancreatitis admitted to our hospital from May 2018 to August 2019 and were randomly divided into a control group and a test group.Forty patients in the control group were treated with octreotide,and 40 patients in the experimental group were treated with ulinastatin combined with octreotide.The treatment effect,safety and inflammatory factor levels of two groups of patients with severe acute pancreatitis were compared.Results The clinical efficacy of patients with severe acute pancreatitis in the experimental group was higher than that in the control group,and the incidence of adverse reactions was lower than that in the control group(P<0.05);the serum levels of IL-6,IL-8 and TNF-αin the two groups were lower than those in the treatment before,and the test group IL-6,IL-8,TNF-αwere lower than the control group,P<0.05.Conclusion Compared with monotherapy,ulinastatin combined with octreotide is safe and effective in the treatment of severe acute pancreatitis,and the serum inflammatory factor levels are significantly improved.
作者
张贵富
ZHANG Guifu(Department of Critical Care Medicine,Donggang Hospital of Traditional Chinese Medicine,Donggang 118300,China)
出处
《中国医药指南》
2021年第3期77-78,共2页
Guide of China Medicine
关键词
重症急性胰腺炎
乌司他丁
奥曲肽
炎性因子
安全性
Severe acute pancreatitis
Ulinastatin
Octreotide
Inflammatory factors
Safety
